HDFC Mutual Fund showcases its HDFC Pharma and Healthcare Fund focused on India's structural healthcare evolution

Mumbai, August 27, 2026: HDFC Asset Management Company Limited (HDFC AMC), investment manager to HDFC Mutual Fund (HDFC MF) and one of India's leading mutual fund houses, referred to the performance of HDFC Pharma and Healthcare Fund, which delivered a CAGR of **30.19% since inception** and a return of **19.01% over the one-year period**, as on July 31, 2026. The fund was launched on October 4, 2023, and seeks to generate long-term capital appreciation by investing predominantly in equity and equity-related instruments of pharma and healthcare companies.

The fund is diversified across pharmaceuticals, hospitals, healthcare service providers, biotechnology, and medical equipment and supplies. India's pharmaceutical and healthcare sector presents a structural growth opportunity, supported by rising domestic demand, increasing healthcare expenditure, expanding export opportunities, and India's position as a global pharmaceutical manufacturing hub. The sector is also witnessing opportunities across complex generics, biosimilars, specialty drugs, contract development and manufacturing, hospitals, diagnostics, and medical technology.

Longer-term trends, including an ageing population, a rising incidence of lifestyle-related diseases, increasing per capita income, and growing insurance penetration, are further supporting healthcare spending and creating opportunities across the broader healthcare ecosystem.

Commenting on the fund's performance, **Mr. Navneet Munot, Managing Director & Chief Executive Officer, HDFC Asset Management Company Limited**, said, *"At HDFC Mutual Fund, our focus remains on identifying businesses that are well positioned to participate in these long-term trends. HDFC Pharma and Healthcare Fund follows a research-led, bottom-up approach that provides the flexibility to identify opportunities across the breadth of the healthcare ecosystem and across market capitalisations."*

HDFC Pharma and Healthcare Fund is managed by **Mr. Nikhil Mathur**. The fund's performance underscores HDFC AMC's focus on identifying and offering investment opportunities across emerging and long-term structural themes.

NAV as on July 31, 2026 Rs. 21.069

PERFORMANCE ^ - Regular Plan - Growth Option

Date	Period	Scheme Returns (%)	Benchmark Returns (%)#	Additional Benchmark Returns (%) ##	Value of ₹ 10,000 invested		
					Scheme (₹)	Benchmark (₹)#	Additional Benchmark (₹)##
Jul 31, 25	Last 1 Year	19.01	12.53	-0.43	11,901	11,253	9,957
Oct 04, 23	Since Inception	30.19	24.14	9.67	21,069	18,418	12,978

^Past performance may or may not be sustained in future and is not a guarantee of any future returns. #BSE Healthcare Index (TRI) ##Nifty 50 Index (TRI). Inception Date: October 4, 2023. The Scheme is managed by Mr. Nikhil Mathur (October 4, 2023). Returns greater than 1 year period are compounded annualized (CAGR). Different plans viz. Regular Plan and Direct Plan have a different expense structure. The expenses of the Direct Plan under the Scheme will be lower to the extent of the distribution expenses / commission charged in the Regular Plan. Load is not taken into consideration for computation of performance. Returns as on July 31, 2026.

For performance of other funds managed by the fund manager, [please click here.]

HDFC Pharma and Healthcare Fund (An open-ended equity scheme investing in Pharma and healthcare companies) is suitable for investors who are seeking*:

- To generate long-term capital appreciation
- Investment predominantly in equity & equity related instruments of Pharma and healthcare companies

*Investors should consult their financial advisers, if in doubt about whether the product is suitable for them.
#For latest riskometer, investors may refer to the Monthly Portfolios disclosed on the website of the Fund viz. www.hdfcfund.com.

Riskometer#



The risk of the scheme is very high

The Schemes being Sectoral/Thematic in nature carries higher risks versus diversified equity mutual funds on account of concentration and sector/theme specific risks

The Scheme Riskometer as on 31st July, 2026.

About HDFC AMC:

HDFC Asset Management Company Limited (HDFC AMC) is an Investment Manager to HDFC Mutual Fund, one of the largest mutual funds in the country. It was incorporated under the Companies Act, 1956 (now governed by Companies Act, 2013), on 10th December 1999 and was approved to act as an Asset Management Company for HDFC Mutual Fund by SEBI on 3rd July 2000. It has other SEBI licenses viz. PMS and AIF. HDFC AMC manages a diversified asset class mix across Equity and Fixed Income/Others. It also has a countrywide network of branches along with a diversified distribution network comprising Banks, Independent Financial Advisors and National Distributors.

HDFC Mutual Fund: SEBI Registration Number: MF/044/00/6

MUTUAL FUND INVESTMENTS ARE SUBJECT TO MARKET RISKS, READ ALL SCHEME RELATED DOCUMENTS CAREFULLY.